Astrana Health, Inc. (ASTH) · Sep 15, 2026 · Guidance

Astrana Health expands AI platform pitch as EBITDA guidance raise loses surprise

Guidance raised — FY2026 adjusted EBITDA floor raised to $255M from $250M

Astrana lays out its AI-native healthcare platform and stronger operating leverage, but the FY2026 EBITDA raise was already disclosed in August.

Astrana is scaling a physician-centric, AI-powered value-based-care platform across more than 20,000 providers and roughly 1.5 million patients, using delegated financial risk and care-management software to improve outcomes while lowering administrative costs. The business story is still execution, not a strategic pivot. The presentation adds detail around the AI operating system, Care Enablement segment, and full-risk contracts, but those are extensions of the existing strategy rather than a newly announced product or market. The filing says Astrana serves “~1.5 million members in value-based arrangements” and highlights 20,000-plus providers (Growth and scale overview). 〔0〕

MetricCurrent filingComparison / prior expectation
FY2026 revenue guidance$3.8B–$4.1BReaffirmed
FY2026 adjusted EBITDA guidance$255M–$280MPrior range: $250M–$280M
FY2026 free cash flow guidance$105M–$132.5MReaffirmed
Q2 2026 revenue$972.5M$654.8M in Q2 2025
Q2 2026 adjusted EBITDA$68.9M$48.1M in Q2 2025
Q2 2026 adjusted EBITDA margin7.1%7.3% in Q2 2025
Q2 2026 G&A as revenue percentage5.6%7.7% in Q2 2025

The only clean financial change is a modest guidance upgrade. Astrana lifted the low end of FY2026 adjusted EBITDA guidance by $5 million to $255 million while leaving the high end, revenue outlook, and free-cash-flow outlook unchanged (FY2026 Guidance Range). That is a positive operational signal, but a narrow one: the prior $250M–$280M range was publicly reiterated in May, and the $255M–$280M range was already disclosed with the August 6 second-quarter release. The filing’s own table shows “$255” to “$280” million for adjusted EBITDA (Guidance). 〔1〕

The underlying operating leverage is improving, though margins have not expanded year over year. Q2 revenue rose to $972.5 million and adjusted EBITDA to $68.9 million, but adjusted EBITDA margin was 7.1% versus 7.3% a year earlier (Summary of Selected Financial Results). The clearer efficiency win is corporate overhead: “G&A improved 210 bps YoY to 5.6% in Q2 2026” (Operating Leverage). 〔2〕

The presentation strengthens the long-term platform narrative without changing near-term risk. Care Enablement is shown at roughly a $340 million revenue run-rate with a 21% operating margin, while 81% of Q2 capitation revenue came from full-risk arrangements (Care Enablement; Risk Progression). Those figures support the thesis that Astrana can turn its software and delegated-risk model into operating leverage, but they are company-reported operating metrics rather than a new contract, acquisition, or quantified acceleration in the outlook.

Bottom line: The filing reinforces Astrana’s AI-enabled value-based-care execution story and records a small EBITDA guidance-floor increase. For the market, however, the financial signal is largely confirmation because the guidance raise and Q2 results were already public in August; the genuinely new content is mostly narrative and operating detail.

What to watch next

Q3 results for the quarter ending September 30, 2026

Original filing on SEC EDGAR

More Astrana Health, Inc. news

Astrana Health expands AI platform pitch as EBITDA guidance raise loses surprise | ASTH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.